Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 38 Myeloid 25 Classical hematology 3 Thoracic 2 Lymphoid 2 Dermatologic 2 Breast 2 Sarcoma 1 Plasma cell 1 Other solid neoplasm 1 NET 1 Head & Neck 1 Genitourinary 1 Gastrointestinal 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 61 lutetium Lu 177 dotatate 53 Magnetic Resonance Spectroscopy 39 pembrolizumab 31 Temozolomide 31 Cisplatin 29 Nivolumab 26 Octreotide 25 lanreotide 24 gallium Ga 68 dotatate 24 cabozantinib 22 pasireotide 21 lenvatinib 20 3-Iodobenzylguanidine 20 Etoposide 19 Sunitinib 18 Specimen Handling 18 Paclitaxel 18 Carboplatin 18 Capecitabine 18 surufatinib 16 Bevacizumab 16 trametinib 15 dabrafenib 15 Sorafenib 14 Doxorubicin 14 Ipilimumab 13 Thyrotropin Alfa 12 Surgical Procedures, Operative 12 Injections 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

decitabine and cedazuridine drug combination × Endocrine × Clear all

NCT05178693 2025-11-24

LANTana

Imperial College London

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡